NCPC(SH:600812)2021-08-24 16:00Financial Performance - The company's operating revenue for the first half of 2021 was CNY 5,583,088,569.47, a decrease of 5.65% compared to CNY 5,917,328,388.94 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 1,005,051.20, down 99.16% from CNY 120,022,080.01 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -30,007,454.21, a decrease of 405.67% compared to CNY 9,816,894.52 in the same period last year[23]. - The net cash flow from operating activities was CNY 243,294,367.88, down 24.23% from CNY 321,096,545.42 in the previous year[23]. - Basic earnings per share decreased by 98.65% to 0.001 CNY from 0.074 CNY in the same period last year[24]. - Diluted earnings per share also decreased by 98.65% to 0.001 CNY from 0.074 CNY in the same period last year[24]. - The weighted average return on equity decreased by 2.07 percentage points to 0.02% compared to the same period last year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 25,539,582,056.45, an increase of 6.72% compared to CNY 23,931,716,749.91 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were CNY 6,077,017,336.78, a decrease of 0.77% from CNY 6,124,327,255.79 at the end of the previous year[23]. - The company’s total liabilities increased by 12.65% to CNY 25,000,000,000, with short-term borrowings accounting for 30.11% of total liabilities[61]. - Long-term equity investments increased by 44.73% to CNY 842,268,114.48, primarily due to an additional investment of CNY 240 million in a financial company[58][62]. Revenue Segments - The company's revenue in the pharmaceutical manufacturing industry reached 1,592.14 billion CNY, a year-on-year increase of 28.7%[34]. - The total profit in the pharmaceutical manufacturing sector was 343.45 billion CNY, reflecting a year-on-year growth of 83.2%[34]. - The biopharmaceutical segment generated revenue of 813 million RMB, representing a year-on-year growth of 11%[41]. - The formulation segment's revenue was 2.69 billion RMB, with nine major products contributing 1.65 billion RMB, accounting for 61% of the formulation revenue[41]. - The agricultural and veterinary medicine and health products segments saw revenue growth of 7.4% and 22.5% respectively[41]. - Export revenue for the first half of the year reached 814 million RMB[51]. Research and Development - The company filed for 10 patents in the first half of the year, including 8 invention patents, with 5 invention patents granted[52]. - The company is advancing key R&D projects, including a recombinant human rabies virus monoclonal antibody injection, which is currently under priority review[52]. - The company is focusing on expanding its product range in new therapeutic areas such as cardiovascular, oncology, kidney disease, and diabetes[48]. - The company is focusing on the development of high-value-added projects in biopharmaceuticals and oncology drugs[29]. Environmental Compliance - The company has implemented strict budget controls and conducted 17 internal quality inspections to ensure product safety and quality[53]. - The company has 11 key pollutant discharge units, with 10 of them publicly disclosing environmental information for the first half of 2021[86]. - The company has implemented a continuous discharge system for wastewater, which is treated to meet standards before being released into the local sewage treatment plant[88]. - The company has established a self-monitoring plan and conducts regular monitoring activities[97]. - The company has completed several environmental protection projects, including the fermentation exhaust treatment project approved on October 18, 2011[97]. - The company has implemented pollution control facilities with a designed treatment capacity of 45,000 m³/h for fermentation tail gas, which is currently operating normally[104]. - The company has established an emergency response plan for environmental incidents, registered under number 130182-2018-031-M[123]. Corporate Governance - The company held its first extraordinary general meeting on April 23, 2021, where 14 resolutions were approved, including the appointment of independent directors and the approval of the 2020 annual financial reports[74]. - On June 16, 2021, the company convened its 2020 annual general meeting, which also approved multiple resolutions related to financial reports and the appointment of the 2021 auditing firm[74]. - The company reported a change in its board of directors, with Zhang Yuxiang elected as chairman and Liu Xinyan appointed as general manager following the resignation of several key executives[78]. - The company did not propose any profit distribution or capital reserve transfer plans for the current period[79]. Risks and Challenges - There were no significant risks that materially affected the company's production and operation during the reporting period[8]. - The company faces risks from a complex pharmaceutical operating environment, including regulatory pressures and rising costs in R&D and production[69]. - The company plans to accelerate structural adjustments and innovate marketing strategies to adapt to industry changes and reduce operational risks[69].